---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-027770"
form_type: "8-K"
ticker: "GRDX"
cik: "0001604191"
company_name: "GridAI Technologies Corp."
filed_at: "2025-03-25T23:59:59+00:00"
generated_at: "2026-05-24T05:48:11.351415+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Entero Therapeutics rescinds 2024 ImmunogenX merger, retains $695K AP; names new CFO

## Summary
- Rescission Agreement with ImmunogenX LLC signed March 24, 2025; unwinds the March 2024 merger.
- Closing conditions include shareholder approval by June 30, 2025, lender consent, and resignation of director Jack Syage.
- Company retains ~$695,000 of ImmunogenX accounts payable; ImmunogenX remains responsible for ~$9.28M secured debt.
- Anna Skowron appointed CFO effective March 3, 2025; brings 14+ years of accounting and financial reporting experience.
- CEO states rescission strengthens balance sheet and refocuses value creation strategy.

## SEC filing metadata
- accession: 0001104659-25-027770
- form_type: 8-K
- ticker: GRDX
- cik: 0001604191
- company_name: GridAI Technologies Corp.
- filed_at: 2025-03-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604191/000110465925027770/0001104659-25-027770-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604191/000110465925027770/tm2510211d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-027770
- JSON: https://secwatch.observer/filing/0001104659-25-027770.json
- Plain text: https://secwatch.observer/filing/0001104659-25-027770.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.